90 results on '"Farowski F"'
Search Results
2. Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease
- Author
-
Bochennek, K., Balan, A., Müller-Scholden, L., Becker, M., Farowski, F., Müller, C., Groll, A. H., and Lehrnbecher, T.
- Published
- 2015
- Full Text
- View/download PDF
3. A quality improvement study on the reduction of central venous catheter-associated bloodstream infections by use of self-disinfecting venous access caps (STERILE)
- Author
-
Cruz-Aguilar, R., Carney, J., Mondaini, V., Vehreschild, M.J.G.T., Griskaitis, M., Salmanton-García, J., Böll, B., Kochanek, M., Seifert, H., Biehl, L.M., Farowski, F., and Publica
- Abstract
Background: Contamination of the catheter hub is an important source of central line-associated bloodstream infections (CLABSI); catheter hub caps incorporating a 70% isopropyl alcohol aim are designed to reduce contamination and hence CLABSI rates. Supporting data in high-risk hematological and oncological patients on the clinical effectiveness of this approach are sparse. Methods: We conducted a before-after single center study accompanying the introduction of such caps at our department. Retrospective data from the year prior to the introduction were compared to 1 year of prospective data. Results: The control and antiseptic barrier cap (ABC) groups consisted of 309 and 289 patients presenting a CLABSI rate of 15.28 and 10.38 per 1,000 catheter days (P=.042), respectively. However, after multivariate analysis, ABCs were not identified as a statistically significant independent protective factor for the occurrence of CLABSI (hazard ratio 0.69, P=.120). There was no significant difference between the groups with respect to time to CLABSI (P=.681), nor the proportion of catheters removed due to suspicion of infection (P=.076). Conclusions: The introduction of ABCs in this high-risk population did not significantly alter CLABSI rates.
- Published
- 2021
4. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome
- Author
-
Vehreschild, J. J., Müller, C., Farowski, F., Vehreschild, M. J. G. T., Cornely, O. A., Fuhr, U., Kreuzer, K.-A., Hallek, M., and Kohl, V.
- Published
- 2012
- Full Text
- View/download PDF
5. Phenotyping non-alcoholic fatty liver disease by the gut microbiota – ready for prime time?
- Author
-
Martin, A, additional, Lang, S, additional, Farowski, F, additional, Wisplinghoff, H, additional, Vehreschild, MJG, additional, Krawczyk, M, additional, Nowag, A, additional, Kretzschmar, A, additional, Herweg, J, additional, Lammert, F, additional, Goeser, T, additional, Kasper, P, additional, Steffen, HM, additional, and Demir, M, additional
- Published
- 2020
- Full Text
- View/download PDF
6. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort
- Author
-
Vehreschild, J. J., Rüping, M. J., Wisplinghoff, H., Farowski, F., Steinbach, A., Sims, R., Stollorz, A., Kreuzer, K.-A., Hallek, M., Bangard, C., and Cornely, O. A.
- Published
- 2010
- Full Text
- View/download PDF
7. Reduced incidence of pneumonia and invasive pulmonary aspergillosis after introduction of posaconazole prophylaxis - data from the cologne AML Cohort: O3.6
- Author
-
Vehreschild, J. J., Rüping, M. J. G. T., Sims, R., Stollorz, A., Farowski, F., Bangard, C., Kreuzer, K.-A., Hallek, M., and Cornely, O. A.
- Published
- 2009
8. Phänotypisierung der nichtalkoholischen Fettlebererkrankung (NAFLD) durch das intestinale Mikrobiom – Sind wir schon so weit?
- Author
-
Martin, A, additional, Lang, S, additional, Farowski, F, additional, Wisplinghoff, H, additional, Vehreschild, MJGT, additional, Krawczyk, M, additional, Nowag, A, additional, Kretzschmar, A, additional, Herweg, J, additional, Lammert, F, additional, Goeser, T, additional, Kasper, P, additional, Steffen, HM, additional, and Demir, M, additional
- Published
- 2019
- Full Text
- View/download PDF
9. Kein signifikanter Einfluss des Fruktosekonsums auf die Zusammensetzung der Darmmikrobiota bei Patienten mit bioptisch gesicherter nichtalkoholischer Fettlebererkrankung
- Author
-
Heinzer, K, additional, Lang, S, additional, Farowski, F, additional, Wisplinghoff, H, additional, Vehreschild, MJGT, additional, Krawczyk, M, additional, Lammert, F, additional, Martin, A, additional, Nowag, A, additional, Kretzschmar, A, additional, Herweg, J, additional, Kasper, P, additional, Goeser, T, additional, Steffen, HM, additional, and Demir, M, additional
- Published
- 2019
- Full Text
- View/download PDF
10. Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation
- Author
-
Farowski, F., Bueker, V., Vehreschild, J. J., Biehl, L., Cruz-Aguilar, R., Scheid, C., Holtick, U., Jazmati, N., Wisplinghoff, H., Cornely, O. A., Vehreschild, M. J. G. T., Farowski, F., Bueker, V., Vehreschild, J. J., Biehl, L., Cruz-Aguilar, R., Scheid, C., Holtick, U., Jazmati, N., Wisplinghoff, H., Cornely, O. A., and Vehreschild, M. J. G. T.
- Abstract
Recent data link the incidence of intestinal GvHD (iGvHD) after allogeneic haematopoietic stem cell transplantation (aSCT) to exposure with piperacillin-tazobactam or imipenem-cilastatin. To assess relevance of timing, duration, sequence and combination of antibiotic treatment in this setting, we applied a time-dependent model to our aSCT cohort. Patients from the prospective Cologne Cohort of Neutropenic Patients (CoCoNut) undergoing aSCT from January 2007 to April 2013 were included into a time-dependent multivariate Cox proportional hazards regression model with backward-stepwise selection. In 399 eligible patients, cumulative antibiotic exposure (hazard ratio (HR) 2.46; 95% confidence interval (95% CI) 1.59-3.81; P < 0.001) and exposure to sequential treatment with penicillin derivatives and carbapenems (HR 6.22, 95% CI 1.27-30.31), but not to the individual classes, were associated with iGvHD at day 100. Glycopeptides were assessed as a risk factor (HR 3.73, 95% CI 1.51-9.19), but not considered independent, since their use was dependent on previous exposure to penicillin derivatives and carbapenems. Patients with iGvHD presented with increased non-relapse mortality at day 365 (HR 3.51; 95% CI 2.10-5.89; P < 0.001). We identified sequential exposure to penicillin derivatives and carbapenems as well as overall exposure to antibiotics as independent risk factors for iGVHD. Confirmation of these findings in larger, prospective cohorts is necessary.
- Published
- 2018
11. First implementation of frozen, capsulized faecal microbiota transplantation for recurrent Clostridium difficile infection into clinical practice in Europe
- Author
-
Tacke, D., Wisplinghoff, H., Kretzschmar, A., Farowski, F., Koehler, P., Herweg, J., Cornely, O.A., and Vehreschild, M.J.G.T.
- Published
- 2015
- Full Text
- View/download PDF
12. Posaconazol: Ein weiteres Triazol-Antimykotikum der neuen Generation?
- Author
-
Kohl, Oliver A. Cornely, Farowski F, and Müller C
- Subjects
Antifungal ,Posaconazole ,chemistry.chemical_compound ,Cytochrome p450 enzyme ,Pharmacokinetics ,chemistry ,medicine.drug_class ,medicine ,Triazole ,General Medicine ,Pharmacology ,medicine.drug - Published
- 2008
- Full Text
- View/download PDF
13. Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation
- Author
-
Farowski, F, primary, Bücker, V, additional, Vehreschild, J J, additional, Biehl, L, additional, Cruz-Aguilar, R, additional, Scheid, C, additional, Holtick, U, additional, Jazmati, N, additional, Wisplinghoff, H, additional, Cornely, O A, additional, and Vehreschild, M J G T, additional
- Published
- 2017
- Full Text
- View/download PDF
14. Micafungin Twice Weekly as Antifungal Prophylaxis in Pediatric Patients at High Risk for Invasive Fungal Disease
- Author
-
Groll, A. H. G., Bochennek, K., Balan, A., Müller-Scholden, L., Becker, M., Farowski, F., Müller, C., and Lehrnbecher, T.
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Current guidelines recommend antifungal prophylaxis for children at high risk for invasive fungal disease (IFD), but the use of polyenes and triazoles is limited by toxicity and drug-drug interactions. Micafungin is well tolerated, but intravenous daily dosing is the current standard. Since recent reports[for full text, please go to the a.m. URL], Infektiologie Update 2014; 24. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)
- Published
- 2014
- Full Text
- View/download PDF
15. Micafungin Twice Weekly as Antifungal Prophylaxis in Pediatric Patients at High Risk for Invasive Fungal Disease
- Author
-
Groll, AHG, Bochennek, K, Balan, A, Müller-Scholden, L, Becker, M, Farowski, F, Müller, C, Lehrnbecher, T, Groll, AHG, Bochennek, K, Balan, A, Müller-Scholden, L, Becker, M, Farowski, F, Müller, C, and Lehrnbecher, T
- Published
- 2014
16. Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis
- Author
-
Cornely, O. A., Vehreschild, J. J., Vehreschild, M. J. G. T., Wuerthwein, G., Arenz, D., Schwartz, S., Heussel, C. P., Silling, G., Mahne, M., Franklin, J., Harnischmacher, U., Wilkens, A., Farowski, F., Karthaus, M., Lehrnbecher, T., Ullmann, A. J., Hallek, M., Groll, A. H., Cornely, O. A., Vehreschild, J. J., Vehreschild, M. J. G. T., Wuerthwein, G., Arenz, D., Schwartz, S., Heussel, C. P., Silling, G., Mahne, M., Franklin, J., Harnischmacher, U., Wilkens, A., Farowski, F., Karthaus, M., Lehrnbecher, T., Ullmann, A. J., Hallek, M., and Groll, A. H.
- Abstract
Our objective was to evaluate the maximum tolerated dose of caspofungin for invasive aspergillosis (IA). The safety and pharmacokinetics of escalating dosages of caspofungin were investigated in IA. Eight patients each received caspofungin 70, 100, 150, or 200 mg once a day (QD). Dose-limiting toxicity (DLT) was defined as the same non-hematological treatment-related adverse event of grade >= 4 in 2 of 8 patients or >= 3 in 4 of 8 patients in a cohort. A total of 46 patients (median age, 61 years; 21 female; 89% with hematological malignancies) received caspofungin (9, 8, 9, and 20 patients in the 70-, 100-, 150-, and 200-mg cohorts) for a median of 24.5 days. Plasma pharmacokinetics were linear across the investigated dosages and followed a two-compartment model, with weight as the covariate on clearance and sex as the covariate on central volume of distribution. Simulated peak plasma concentrations at steady state ranged from 14.2 to 40.6 mg/liter (28%), trough concentrations from 4.1 to 11.8 mg/liter (58%), and area under the concentration-time curve from 175 to 500 mg/liter/h (32%) (geometric mean, geometric coefficient of variation). Treatment was well tolerated without dose-limiting toxicity. The rate of complete or partial responses was 54.3%, and the overall mortality at 12-week follow-up was 28.3%. In first-line treatment of invasive aspergillosis, daily doses of up to 200 mg caspofungin were well tolerated and the maximum tolerated dose was not reached. Pharmacokinetics was linear. Response rates were similar to those previously reported for voriconazole and liposomal amphotericin.
- Published
- 2011
17. Intracellular concentrations of azoles and echinocandins in different compartments of the peripheral blood
- Author
-
Farowski, F, Müller, C, Rüping, MJ, Vehreschild, JJ, Cornely, OA, Farowski, F, Müller, C, Rüping, MJ, Vehreschild, JJ, and Cornely, OA
- Published
- 2010
18. Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis
- Author
-
Cornely, O. A., primary, Vehreschild, J. J., additional, Vehreschild, M. J. G. T., additional, Würthwein, G., additional, Arenz, D., additional, Schwartz, S., additional, Heussel, C. P., additional, Silling, G., additional, Mahne, M., additional, Franklin, J., additional, Harnischmacher, U., additional, Wilkens, A., additional, Farowski, F., additional, Karthaus, M., additional, Lehrnbecher, T., additional, Ullmann, A. J., additional, Hallek, M., additional, and Groll, A. H., additional
- Published
- 2011
- Full Text
- View/download PDF
19. Dose Escalation of Caspofungin for Invasive Aspergillosis - A Phase II Trial
- Author
-
Cornely, O. A, primary, Vehreschild, J. J, additional, Rüping, M. J, additional, Schwartz, S., additional, Heussel, C., additional, Silling, Gerda, additional, Franklin, J., additional, Farowski, F., additional, Lehrnbecher, T., additional, Ullmann, A. J, additional, Groll, A., additional, and Karthaus, Meinolf, additional
- Published
- 2010
- Full Text
- View/download PDF
20. Posaconazol: Ein weiteres Triazol-Antimykotikum der neuen Generation?
- Author
-
Müller, C, primary, Kohl, V, additional, Farowski, F, additional, and Cornely, O, additional
- Published
- 2008
- Full Text
- View/download PDF
21. Factors influencing pharmacokinetics of prophylactic posaconazole oral solution in patients with acute myeloid leukemia or myelodysplastic syndrome
- Author
-
Vehreschild, J. -J, Mueller, C., Farowski, F., Vehreschild, M. J. G. T., Oliver Cornely, Fuhr, U., Kreuzer, K. -A, Hallek, M., and Kohl, V.
22. Reduced incidence of pneumonia and invasive pulmonary aspergillosis after introduction of posaconazole prophylaxis: data from the Cologne AML cohort
- Author
-
Jörg Janne Vehreschild, Rueping, M. J. G. T., Sims, R., Stollorz, A., Farowski, F., Bangard, C., Kreutzer, K. -A, Hallek, M., and Cornely, O. A.
23. A phase II dose escalation study of caspofungin for invasive aspergillosis
- Author
-
Cornely, O. A., Vehreschild, J. J., Rueping, M. J. G. T., Arenz, D., Schwartz, S., Heussel, C. -P, Silling, G., Mahne, M., Franklin, J., Harnischmacher, U., Wilkens, A., Farowski, F., Karthaus, M., Lehrnbecher, T., Ullmann, A. J., Michael Hallek, and Groll, A.
24. Intracellular concentrations of anidulafungin and micafungin
- Author
-
Farowski, F., Mueller, C., Vehreschild, M. J. G. T., Vehreschild, J. J., and Oliver Cornely
25. Changes in the epidemiology of invasive pulmonary aspergillosis after introduction of posaconazole prophylaxis in AML/MDS patients
- Author
-
Vehreschild, J., Sims, R., Stollorz, A., Prasse, S., Rueping, M., Farowski, F., Peter Frommolt, Staib, P., Hallek, M., and Cornely, O.
26. Population pharmacokinetics of caspofungin in a phase II dose escalation study
- Author
-
Groll, A. H., Vehreschild, J. J., Vehreschild, M. J. G., Farowski, F., Oliver Cornely, and Wuerthwein, G.
27. Investigation of gut microbiota composition in humans carrying blastocystis subtypes 1 and 2 and Entamoeba hartmanni.
- Author
-
Antonetti L, Berrilli F, Di Cristanziano V, Farowski F, Daeumer M, Eberhardt KA, Santoro M, Federici M, and D'Alfonso R
- Abstract
The composition of human gut microbiota is dominated by bacteria which have been extensively studied. The role of intestinal eukaryote microorganisms like Blastocystis, however, remains under investigation. Moreover, the potential impact on gut health related to Blastocystis presence was primarily investigated in symptomatic individuals mainly from industrialized countries, and appears to be mostly beneficial to the host microbiota. Data from surveys conducted in underdeveloped countries with higher prevalence and from asymptomatic individuals could therefore be valuable. The aim of this preliminary study was to analyze the composition of the gut microbiota in relation to the protozoa Blastocystis ST1 and ST2 and Entamoeba hartmanni carriage in asymptomatic subjects living in a semi-urban area of Côte d'Ivoire to add data into the ongoing debate on the role of Blastocystis in host health. The amplification of the V3 and V4 regions of bacterial 16S rDNA genes was performed to obtain the gut microbiota composition, and differential analyses on alpha and beta diversity were performed from the phylum to genus taxonomic level. The analysis revealed that individuals positive for both protozoa exhibited higher alpha and beta diversity compared to those who tested negative. Additionally, their bacterial composition showed a reduction in Bacteroides and an increase in Prevotella 9. Relative abundances of some OTUs, particularly Faecalibacterium, observed in individuals who tested positive for protozoa, were correlated with a good state of health of the gut microbiota. Blastocystis ST1 and ST2 associated with E. hartmanni thus appeared to be related to a state of intestinal eubiosis., Competing Interests: Declarations. Ethics approval and consent to participate: The scientific reasons and the protocol of the study were reviewed and approved by the Medical Director of the Don Orione Center in Bonoua and all Directors of each service on the date 20.01.2014. This research was conducted without any “Invasive act”, affecting the physical, psychological, or moral integrity of the participants. The identity of each participant was protected by the attribution of an anonymous code to each stool sample collected. All experiments were performed following the ethical standards established by the Universal Declaration of Human Rights (1948), and the Declaration of Helsinki (1964), and its successive amendments were complied with. Consent for publication: Participation of adults and children occurred voluntarily. A verbal agreement on the methods and purposes of the study was acquired before proceeding with sampling collection by adults and parents/guardians of children. A local dialect interpreter of dialect was used to explain the study’s aims, procedures, and significance when necessary. All participants were assured that all data were analyzed anonymously, and the human biological sample would provide data exclusively on intestinal microorganisms and not on human tissues. Competing interest: The authors declare no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
28. Antibiotics-Induced Intestinal Immunomodulation Attenuates Experimental Autoimmune Neuritis (EAN).
- Author
-
Sprenger-Svačina A, Klein I, Svačina MKR, Bobylev I, Kohle F, Schneider C, Schweitzer F, Piekarek N, Barham M, Vehreschild MJGT, Lehmann HC, and Farowski F
- Subjects
- Animals, Rats, Male, Rats, Inbred Lew, Neuritis, Autoimmune, Experimental immunology, Neuritis, Autoimmune, Experimental drug therapy, Gastrointestinal Microbiome drug effects, Anti-Bacterial Agents pharmacology, Immunomodulation drug effects
- Abstract
Background: The composition of gut microbiota plays a pivotal role in priming the immune system and thus impacts autoimmune diseases. Data on the effects of gut bacteria eradication via systemic antibiotics on immune neuropathies are currently lacking. This study therefore assessed the effects of antibiotics-induced gut microbiota alterations on the severity of experimental autoimmune neuritis (EAN), a rat model of Guillain-Barré Syndrome (GBS). Myelin P0 peptide 180-199 (P0 180-199)-induced EAN severity was compared between adult Lewis rats (12 weeks old) that received drinking water with or without antibiotics (colistin, metronidazole, vancomycin) and healthy rats, beginning antibiotics treatment immediately after immunization (day 0), and continuing treatment for 14 consecutive days. Neuropathy severity was assessed via a modified clinical score, and then related to gut microbiota alterations observed after fecal 16S rRNA gene sequencing at baseline and after EAN induction. Effectors of gut mucosal and endoneurial immunity were assessed via immunostaining. EAN rats showed increased gut mucosal permeability alongside increased mucosal CD8
+ T cells compared to healthy controls. Antibiotics treatment alleviated clinical EAN severity and reduced endoneurial T cell infiltration, decreased gut mucosal CD8+ T cells and increased gut bacteria that may be associated with anti-inflammatory mechanisms, like Lactobacillus or Parasutterella. Our findings point out a relation between gut mucosal immunity and the pathogenesis of EAN, and indicate that antibiotics-induced intestinal immunomodulation might be a therapeutic approach to alleviate autoimmunity in immune neuropathies. Further studies are warranted to evaluate the clinical transferability of these findings to patients with GBS., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
29. Torque teno virus-DNA load as individual cytomegalovirus risk assessment parameter upon allogeneic hematopoietic stem cell transplantation.
- Author
-
Spiertz A, Tsakmaklis A, Farowski F, Knops E, Heger E, Wirtz M, Kaiser R, Holtick U, Vehreschild MJGT, and Di Cristanziano V
- Subjects
- Humans, Cytomegalovirus, DNA, Viral, Risk Assessment, Viral Load, Torque teno virus genetics, Cytomegalovirus Infections diagnosis, Cytomegalovirus Infections etiology, Hematopoietic Stem Cell Transplantation adverse effects
- Abstract
Background: Immune recovery following allogeneic hematopoietic stem cell transplantation (allo-HSCT) decisively influences the occurrence of opportunistic infections, one of the leading causes of death among this group of patients. Yet, today, there are no laboratory parameters mirroring immune function sufficiently. Torque teno virus (TTV) has already proven itself as a functional immune marker in other settings., Aims: In this analysis, we investigated whether monitoring of TTV-DNA load in whole blood is able to provide additional information on the capacity of the immune system to control cytomegalovirus (CMV) replication in allo-HSCT recipients., Methods: Whole blood samples from 59 patients were collected upon allo-HSCT (between Day -7 and +10), on Day +14, +21, +28, +56, +90, and +365 post-transplant. TTV-DNA loads and other relevant clinical information were correlated with the risk of CMV infections or reactivations, defined by evidence of viral replication in blood., Results: CMV serostatus of the recipient and a TTV load below 1000 copies/mL upon allo-HSCT were significantly associated with an increased incidence of CMV infection or reactivation., Conclusions: Quantification of TTV load in the early phase of allo-HSCT procedure could provide additional information in order to identify patients at risk for CMV infection or reactivation., (© 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
30. TIGIT + NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients.
- Author
-
Tsakmaklis A, Farowski F, Zenner R, Lesker TR, Strowig T, Schlößer H, Lehmann J, von Bergwelt-Baildon M, Mauch C, Schlaak M, Knuever J, Schweinsberg V, Heinzerling LM, and Vehreschild MJGT
- Subjects
- Humans, Immune Checkpoint Inhibitors pharmacology, Immune Checkpoint Inhibitors therapeutic use, Prospective Studies, Killer Cells, Natural, Receptors, Immunologic, Melanoma drug therapy, Gastrointestinal Microbiome, Skin Neoplasms drug therapy
- Abstract
Background: Composition of the intestinal microbiota has been correlated to therapeutic efficacy of immune checkpoint inhibitors (ICI) in various cancer entities including melanoma. Prediction of the outcome of such therapy, however, is still unavailable. This prospective, non-interventional study was conducted in order to achieve an integrated assessment of the connection between a specific intestinal microbiota profile and antitumor immune response to immune checkpoint inhibitor therapy (anti-PD-1 and/or anti-CTLA-4) in melanoma patients., Methods: We assessed blood and stool samples of 29 cutaneous melanoma patients who received immune checkpoint inhibitor therapy. For functional and phenotypical immune analysis, 12-color flow cytometry and FluoroSpot assays were conducted. Gut microbiome was analyzed with shotgun metagenomics sequencing. To combine clinical, microbiome and immune variables, we applied the Random Forest algorithm., Results: A total of 29 patients was analyzed in this study, among whom 51.7% (n = 15) reached a durable clinical benefit. The Immune receptor TIGIT is significantly upregulated in T cells (p = 0.0139) and CD56
high NK cells (p = 0.0037) of responders. Several bacterial taxa were associated with response (e.g. Ruminococcus torques) or failure (e.g. Barnesiella intestinihominis) to immune therapy. A combination of two microbiome features (Barnesiella intestinihominis and the Enterobacteriaceae family) and one immune feature (TIGIT+ CD56high NK cells) was able to predict response to ICI already at baseline (AUC = 0.85; 95% CI: 0.841-0.853)., Conclusions: Our results reconfirm a link between intestinal microbiota and response to ICI therapy in melanoma patients and furthermore point to TIGIT as a promising target for future immunotherapies., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
31. The gut microbiome in intravenous immunoglobulin-treated chronic inflammatory demyelinating polyneuropathy.
- Author
-
Svačina MKR, Sprenger-Svačina A, Tsakmaklis A, Rüb AM, Klein I, Wüstenberg H, Fink GR, Lehmann HC, Vehreschild MJGT, and Farowski F
- Subjects
- Humans, Female, Middle Aged, Aged, Adult, Male, Immunoglobulins, Intravenous therapeutic use, Pilot Projects, RNA, Ribosomal, 16S genetics, Chronic Disease, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating therapy, Gastrointestinal Microbiome
- Abstract
Background and Purpose: The gut microbiome is involved in autoimmunity. Data on its composition in chronic inflammatory demyelinating polyneuropathy (CIDP), the most common chronic autoimmune disorder of peripheral nerves, are currently lacking., Methods: In this monocentric exploratory pilot study, stool samples were prospectively collected from 16 CIDP patients (mean age 58 ± 10 years, 25% female) before and 1 week after administration of intravenous immunoglobulin (IVIg). Gut microbiota were analyzed via bacterial 16S rRNA gene sequencing and compared to 15 age-matched healthy subjects (mean age 59 ± 15 years, 66% female)., Results: The gut microbiota of CIDP patients showed an increased alpha-diversity (p = 0.005) and enrichment of Firmicutes, such as Blautia (p = 0.0004), Eubacterium hallii (p = 0.0004), or Ruminococcus torques (p = 0.03), and of Actinobacteriota (p = 0.03) compared to healthy subjects. IVIg administration did not alter the gut microbiome composition in CIDP in this short-term observation (p = 0.95)., Conclusions: The gut microbiome in IVIg-treated CIDP shows distinct features, with increased bacterial diversity and enrichment of short-chain fatty acid producing Firmicutes. IVIg had no short-term impact on the gut microbiome in CIDP patients. As the main limitation of this exploratory pilot study was small cohort size, future studies also including therapy-naïve patients are warranted to verify our findings and to explore the impact of long-term IVIg treatment on the gut microbiome in CIDP., (© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.)
- Published
- 2023
- Full Text
- View/download PDF
32. Dietary omega-6/omega-3 ratio is not associated with gut microbiota composition and disease severity in patients with nonalcoholic fatty liver disease.
- Author
-
Heinzer K, Lang S, Farowski F, Wisplinghoff H, Vehreschild MJGT, Martin A, Nowag A, Kretzschmar A, Scholz CJ, Roderburg C, Mohr R, Tacke F, Kasper P, Goeser T, Steffen HM, and Demir M
- Subjects
- Humans, RNA, Ribosomal, 16S genetics, Cross-Sectional Studies, Bacteria genetics, Severity of Illness Index, Non-alcoholic Fatty Liver Disease etiology, Gastrointestinal Microbiome physiology, Fatty Acids, Omega-3
- Abstract
In this cross-sectional study, we hypothesized that a high dietary ratio of omega-6 (n-6) to omega-3 (n-3) fatty acids could be associated with an altered gut bacterial composition and with the disease severity in patients with nonalcoholic fatty liver disease (NAFLD). A total of 101 NAFLD patients were included in the study, of which 63 underwent a liver biopsy. All 101 patients completed a 14-day food and activity record. Ebispro 2016 professional software was used to calculate individual macronutrients and micronutrients consumed. Patients were grouped into 3 quantiles (Q) according to a low (Q1: <6.1, n = 34), moderate (Q2: 6.1-7.8, n = 33), or high (Q3: >7.8, n = 34) dietary n-6/n-3 ratio. Stool samples were analyzed using 16S rRNA gene sequencing. Spearman correlation coefficients and principal coordinate analysis were used to detect differences in the bacterial composition of the gut microbiota. The median dietary n-6/n-3 ratio of all patients was 6.7 (range, 3.1-14.9). No significant associations between the dietary n-6/n-3 ratio and the gut microbiota composition or disease severity were observed. However, the abundance of specific bacteria such as Catenibacterium or Lactobacillus ruminis were found to be positively correlated and the abundance of Clostridium were negatively correlated with dietary n-6 fatty acid intake. The results indicate that a high dietary n-6/n-3 ratio is probably not a highly relevant factor in the pathogenesis of human NAFLD. Further studies are needed to clarify the importance of interactions between gut bacterial taxa and n-6 fatty acids in the pathophysiology of NAFLD., Competing Interests: Declaration of Competing Interest The authors declare that they have no conflict of interest., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
33. Longitudinal variability in the urinary microbiota of healthy premenopausal women and the relation to neighboring microbial communities: A pilot study.
- Author
-
Biehl LM, Farowski F, Hilpert C, Nowag A, Kretzschmar A, Jazmati N, Tsakmaklis A, Wieters I, Khodamoradi Y, Wisplinghoff H, and Vehreschild MJGT
- Subjects
- Adult, Bacteria genetics, Bacteria isolation & purification, DNA, Ribosomal genetics, Feces microbiology, Female, Gastrointestinal Microbiome, Healthy Volunteers, Humans, Longitudinal Studies, Phylogeny, Pilot Projects, Urethra microbiology, Vagina microbiology, Young Adult, Bacteria classification, Premenopause urine, RNA, Ribosomal, 16S genetics, Sequence Analysis, DNA methods, Urine microbiology
- Abstract
Background: The understanding of longitudinal changes in the urinary microbiota of healthy women and its relation to intestinal microbiota is limited., Methods: From a cohort of 15 premenopausal women without known urogenital disease or current symptoms, we collected catheter urine (CU), vaginal and periurethral swabs, and fecal samples on four visits over six months. Additionally, ten participants provided CU and midstream urine (MU) to assess comparability. Urine was subjected to expanded culture. 16S rRNA gene sequencing was performed on all urine, fecal, and selected vaginal and periurethral samples. Sequence reads were processed (DADA2 pipeline) and analyzed using QIIME 2 and R., Results: Relative abundances of urinary microbiota were variable over 6-18 months. The degree of intraindividual variability of urinary microbiota was higher than that found in fecal samples. Still, nearly half of the observed beta diversity of all urine samples could be attributed to differences between volunteers (R2 = 0.48, p = 0.001). After stratification by volunteer, time since last sexual intercourse was shown to be a factor significantly contributing to beta diversity (R2 = 0.14, p = 0.001). We observed a close relatedness of urogenital microbial habitats and a clear distinction from intestinal microbiota in the overall betadiversity analysis. Microbiota compositions derived from MU differed only slightly from CU compositions. Within this analysis of low-biomass samples, we identified contaminating sequences potentially stemming from sequencing reagents., Conclusions: Results from our longitudinal cohort study confirmed the presence of a rather variable individual urinary microbiota in premenopausal women. These findings from catheter urine complement previous observations on temporal dynamics in voided urine. The higher intraindividual variability of urinary microbiota as compared to fecal microbiota will be a challenge for future studies investigating associations with urogenital diseases and aiming at identifying pathogenic microbiota signatures., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: LMB has received lecture honoraria from Astellas and Merck/MSD, and travel grants from 3M and Gilead. MJGTV reports grants and personal fees from 3M, Alb Fils Kliniken GmbH, Astellas Pharma, Basilea, bioMérieux, DaVolterra, Gilead Sciences, Ferring, Glycom, Heel, MaaT Pharma, Merck/MSD, Organobalance, Pfizer, Roche Pharma, Seres Therapeutics. YK has received lecture honoraria from Merck/MSD and Gilead, and travel grants from Gilead. All remaining authors have declared no conflicts of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2022
- Full Text
- View/download PDF
34. Analysis of Human Gut Microbiota Composition Associated to the Presence of Commensal and Pathogen Microorganisms in Côte d'Ivoire.
- Author
-
Di Cristanziano V, Farowski F, Berrilli F, Santoro M, Di Cave D, Glé C, Daeumer M, Thielen A, Wirtz M, Kaiser R, Eberhardt KA, Vehreschild MJGT, and D'Alfonso R
- Abstract
Background: The human gut microbiota is a microbial ecosystem contributing to the maintenance of host health with functions related to immune and metabolic aspects. Relations between microbiota and enteric pathogens in sub-Saharan Africa are scarcely investigated. The present study explored gut microbiota composition associated to the presence of common enteric pathogens and commensal microorganisms, e.g., Blastocystis and Entamoeba species, in children and adults from semi-urban and non-urban localities in Côte d'Ivoire., Methods: Seventy-six stool samples were analyzed for microbiota composition by 16S rRDNA sequencing. The presence of adeno-, entero-, parechoviruses, bacterial and protozoal pathogens, Blastocystis , and commensal Entamoeba species, was analyzed by different molecular assays., Results: Twelve individuals resulted negative for any tested microorganisms, 64 subjects were positive for one or more microorganisms. Adenovirus, enterovirus, enterotoxigenic Escherichia coli (ETEC), and Blastocystis were frequently detected., Conclusions: The bacterial composition driven by Prevotellaceae and Ruminococcaceae confirmed the biotype related to the traditional dietary and cooking practices in low-income countries. Clear separation in UniFrac distance in subjects co-harboring Entamoeba hartmanni and Blastocystis was evidenced. Alpha diversity variation in negative control group versus only Blastocystis positive suggested its possible regulatory contribution on intestinal microbiota. Pathogenic bacteria and virus did not affect the positive outcome of co-harbored Blastocystis .
- Published
- 2021
- Full Text
- View/download PDF
35. Fecal microbiota transfer for refractory intestinal graft-versus-host disease - Experience from two German tertiary centers.
- Author
-
Goeser F, Sifft B, Stein-Thoeringer C, Farowski F, Strassburg CP, Brossart P, Higgins PG, Scheid C, Wolf D, Holderried TAW, Vehreschild MJGT, and Cruz Aguilar MR
- Subjects
- Adult, Aged, Biodiversity, Disease Management, Female, Gastrointestinal Diseases diagnosis, Gastrointestinal Microbiome, Germany, Graft vs Host Disease diagnosis, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods, Humans, Male, Middle Aged, Tertiary Care Centers, Transplantation, Homologous, Treatment Outcome, Fecal Microbiota Transplantation methods, Gastrointestinal Diseases etiology, Gastrointestinal Diseases therapy, Graft vs Host Disease etiology, Graft vs Host Disease therapy
- Abstract
Rationale: Steroid refractory graft-vs-host disease (sr-GvHD) represents a challenging complication after allogeneic hematopoietic cell transplantation (allo-HCT). Intestinal microbiota (IM) diversity and dysbiosis were identified as influencing factors for the development of acute GvHD. Fecal microbiota transfer (FMT) is hypothesized to restore IM dysbiosis, but there is limited knowledge about the significance of FMT in the treatment of sr-GvHD., Objectives: We studied the effects of FMT on sr-GvHD in allo-HCT patients from two German tertiary clinical centers (n = 11 patients; period: March 2017 until July 2019). To assess safety and clinical efficacy, we analyzed clinical data pre- and post-FMT (day -14 to +30 relative to FMT). Moreover, IM were analyzed in donor samples and in a subset of patients pre- and post-FMT by 16S rRNA sequencing., Results: Post-FMT, we observed no intervention-associated, systemic inflammatory responses and only minor side effects (5/11 patients: abdominal pain and transformation of peristalsis-each 3/11 and vomiting-1/11). Stool frequencies and volumes were significantly reduced [pre- vs post-FMT (d14): P < .05, respectively] as well as clear attenuation regarding both grading and staging of sr-GvHD was present upon FMT. Moreover, IM analyses revealed an increase of alpha diversity as well as a compositional shifts toward the donor post-FMT., Conclusions: In our study, we observed positive effects on sr-GVHD after FMT without the occurrence of major adverse events. Although these findings are in line with published data on beneficial effects of FMT in sr-GvHD, further randomized clinical studies are urgently needed to better define the clinical validity including mode of action., (© 2021 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
36. Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease.
- Author
-
Lang S, Martin A, Zhang X, Farowski F, Wisplinghoff H, J G T Vehreschild M, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Mohr R, Lammert F, Tacke F, Schnabl B, Goeser T, Steffen HM, and Demir M
- Subjects
- Aged, Biopsy, Cross-Sectional Studies, Diet, Humans, Lipase genetics, Liver, Membrane Proteins genetics, Polymorphism, Single Nucleotide, Gastrointestinal Microbiome, Non-alcoholic Fatty Liver Disease genetics
- Abstract
Background and Aims: Non-alcoholic fatty liver disease (NAFLD) is a global health burden. Risk factors for disease severity include older age, increased body mass index (BMI), diabetes, genetic variants, dietary factors and gut microbiota alterations. However, the interdependence of these factors and their individual impact on disease severity remain unknown., Methods: In this cross-sectional study, we performed 16S gene sequencing using fecal samples, collected dietary intake, PNPLA3 gene variants and clinical and liver histology parameters in a well-described cohort of 180 NAFLD patients. Principal component analyses were used for dimensionality reduction of dietary and microbiota data. Simple and multiple stepwise ordinal regression analyses were performed., Results: Complete data were available for 57 NAFLD patients. In the simple regression analysis, features associated with the metabolic syndrome had the highest importance regarding liver disease severity. In the multiple regression analysis, BMI was the most important factor associated with the fibrosis stage (OR per kg/m
2 : 1.23, 95% CI 1.10-1.37, P < .001). The PNPLA3 risk allele had the strongest association with the histological grade of steatosis (OR 5.32, 95% CI 1.56-18.11, P = .007), followed by specific dietary patterns. Low abundances of Faecalibacterium, Bacteroides and Prevotella and high abundances of Gemmiger were associated with the degree of inflammation, ballooning and stages of fibrosis, even after taking other cofactors into account., Conclusions: BMI had the strongest association with histological fibrosis, but PNPLA3 gene variants, gut bacterial features and dietary factors were all associated with different histology features, which underscore the multifactorial pathogenesis of NAFLD., (© 2021 The Authors. Liver International published by John Wiley & Sons Ltd.)- Published
- 2021
- Full Text
- View/download PDF
37. A quality improvement study on the reduction of central venous catheter-associated bloodstream infections by use of self-disinfecting venous access caps (STERILE).
- Author
-
Cruz-Aguilar R, Carney J, Mondaini V, Vehreschild MJGT, Griskaitis M, Salmanton-García J, Böll B, Kochanek M, Seifert H, Biehl LM, and Farowski F
- Subjects
- Humans, Prospective Studies, Quality Improvement, Retrospective Studies, Bacteremia epidemiology, Bacteremia prevention & control, Catheter-Related Infections epidemiology, Catheter-Related Infections prevention & control, Catheterization, Central Venous adverse effects, Central Venous Catheters adverse effects, Sepsis epidemiology, Sepsis prevention & control
- Abstract
Background: Contamination of the catheter hub is an important source of central line-associated bloodstream infections (CLABSI); catheter hub caps incorporating a 70% isopropyl alcohol aim are designed to reduce contamination and hence CLABSI rates. Supporting data in high-risk hematological and oncological patients on the clinical effectiveness of this approach are sparse., Methods: We conducted a before-after single center study accompanying the introduction of such caps at our department. Retrospective data from the year prior to the introduction were compared to 1 year of prospective data., Results: The control and antiseptic barrier cap (ABC) groups consisted of 309 and 289 patients presenting a CLABSI rate of 15.28 and 10.38 per 1,000 catheter days (P= .042), respectively. However, after multivariate analysis, ABCs were not identified as a statistically significant independent protective factor for the occurrence of CLABSI (hazard ratio 0.69, P= .120). There was no significant difference between the groups with respect to time to CLABSI (P= .681), nor the proportion of catheters removed due to suspicion of infection (P= .076)., Conclusions: The introduction of ABCs in this high-risk population did not significantly alter CLABSI rates., (Copyright © 2020 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
38. Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?
- Author
-
Demir M, Lang S, Martin A, Farowski F, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Scholz CJ, Kretzschmar A, Roderburg C, Lammert F, Goeser T, Kasper P, and Steffen HM
- Subjects
- Adult, Bacteroidetes, Cross-Sectional Studies, Female, High-Throughput Nucleotide Sequencing methods, Humans, Lactobacillaceae, Male, Prospective Studies, RNA, Ribosomal, 16S, Ruminococcus, Veillonella, Young Adult, Gastrointestinal Microbiome genetics, Non-alcoholic Fatty Liver Disease genetics, Non-alcoholic Fatty Liver Disease microbiology, Phenotype
- Abstract
Background and Aim: Several studies observed alterations in the gut microbiota in patients with non-alcoholic fatty liver disease (NAFLD). However, analyzed patient populations and methods strongly differ among these studies. The aim of this study was to prove the reproducibility of published results and to provide a detailed overview of all findings in our NAFLD cohort using next generation sequencing methods., Methods: The individual taxonomic microbiota composition of fecal samples from 90 NAFLD patients and 21 healthy controls was analyzed using 16S rRNA gene sequencing. Study participants were grouped according to their disease stage and compared regarding their gut microbiota composition. Studies were identified from PubMed listed publications, and the results were compared with the findings in our cohort., Results: Results from 13 identified studies were compared with our data. A decreased abundance of the Bacteroidetes and Ruminococcaceae as well as an increased abundance of Lactobacillaceae and Veillonellaceae and Dorea were the most frequently reported changes among NAFLD patients in 4/13, 5/13, 4/13, 2/13, and 3/13 studies, respectively. Even though these alterations in the gut microbiota composition were also observed in our patient cohort, the majority of published differences could not be reproduced, neither in our own nor in other NAFLD cohort studies., Conclusion: Despite repeatedly reproduced abundance patterns of specific bacteria, the heterogeneous study results did not reveal a consistent disease specific gut microbiota signature. Further prospective studies with homogenous patient cohorts and standardized methods are necessary to phenotype NAFLD by the gut microbiota., (© 2020 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
39. Antibiotic Resistance and Mobile Genetic Elements in Extensively Drug-Resistant Klebsiella pneumoniae Sequence Type 147 Recovered from Germany.
- Author
-
Xanthopoulou K, Carattoli A, Wille J, Biehl LM, Rohde H, Farowski F, Krut O, Villa L, Feudi C, Seifert H, and Higgins PG
- Abstract
Mobile genetic elements (MGEs), especially multidrug-resistance plasmids, are major vehicles for the dissemination of antimicrobial resistance determinants. Herein, we analyse the MGEs in three extensively drug-resistant (XDR) Klebsiella pneumoniae isolates from Germany. Whole genome sequencing (WGS) is performed using Illumina and MinION platforms followed by core-genome multi-locus sequence typing (MLST). The plasmid content is analysed by conjugation, S1-pulsed-field gel electrophoresis (S1-PFGE) and Southern blot experiments. The K. pneumoniae isolates belong to the international high-risk clone ST147 and form a cluster of closely related isolates. They harbour the bla
OXA-181 carbapenemase on a ColKP3 plasmid, and 12 antibiotic resistance determinants on an multidrug-resistant (MDR) IncR plasmid with a recombinogenic nature and encoding a large number of insertion elements. The IncR plasmids within the three isolates share a high degree of homology, but present also genetic variations, such as inversion or deletion of genetic regions in close proximity to MGEs. In addition, six plasmids not harbouring any antibiotic resistance determinants are present in each isolate. Our study indicates that genetic variations can be observed within a cluster of closely related isolates, due to the dynamic nature of MGEs. The mobilome of the K. pneumoniae isolates combined with the emergence of the XDR ST147 high-risk clone have the potential to become a major challenge for global healthcare.- Published
- 2020
- Full Text
- View/download PDF
40. Changes in the cervical microbiota of cervical cancer patients after primary radio-chemotherapy.
- Author
-
Tsakmaklis A, Vehreschild M, Farowski F, Trommer M, Kohler C, Herter J, and Marnitz S
- Subjects
- Adult, Female, Humans, Middle Aged, Young Adult, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms radiotherapy
- Abstract
Objective: Several recent studies have identified a potential interaction between the vaginal microbiota and gynecological cancers, but little is known about the cervical microbiota and its changes during cancer treatment. Therefore, the aim of the study was to evaluate the quantitative and qualitative changes of cervical microbiota in patients undergoing concurrent chemotherapy and radiation treatment for locally advanced cervical cancer., Methods: Cervical cytobrush samples of 15 cervical patients undergoing chemoradiation treatment were collected 1 day before starting external beam radiation therapy and on the day of the last fraction of brachytherapy. After DNA extraction, 16S rRNA amplicon sequencing of the V3-V4 region was performed on the MiSeq platform, followed by data processing and statistical analyses concerning the alpha and beta diversity of 16 samples (7 samples were excluded because of incomplete sample sets)., Results: The amount of amplicon yield after polymerase chain reaction analysis in post-radiation samples was significantly lower compared with the baseline samples (pre 31.49±24.07 ng/µl; post 1.33±1.94 ng/µl; p=0.007). A comparison of pre-treatment and post-treatment samples did not show significant differences regarding beta diversity (weighted UniFrac). There was no significant difference in alpha diversity, which is used to characterize species diversity within a particular community and takes into account both number and abundance (Shannon Diversity Index pre-treatment samples: 2.167±0.7504 (95% CI 1.54 to 2.79); post-treatment samples: 1.97±0.43 (95% CI 1.61 to 2.33); p=0.38). Interindividual differences in patients could partly explain some variation of the samples (permutational multivariate analysis of variance)., Conclusion: There was a strong reduction in cervical bacterial loads after chemoradiation. Neither alpha nor beta diversity varied significantly when baseline samples were compared with post-treatment samples., Competing Interests: Competing interests: None declared., (© IGCS and ESGO 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
41. Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools.
- Author
-
Lang S, Farowski F, Martin A, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Lammert F, Goeser T, Steffen HM, and Demir M
- Subjects
- Adult, Aged, Cohort Studies, Disease Progression, Elasticity Imaging Techniques, Female, Fibrosis, Humans, Male, Middle Aged, Predictive Value of Tests, Prognosis, Risk, Sequence Analysis, RNA, Gastrointestinal Microbiome genetics, Liver pathology, Non-alcoholic Fatty Liver Disease diagnosis, RNA, Ribosomal, 16S genetics
- Abstract
Liver fibrosis is the major determinant of liver related complications in patients with non-alcoholic fatty liver disease (NAFLD). A gut microbiota signature has been explored to predict advanced fibrosis in NAFLD patients. The aim of this study was to validate and compare the diagnostic performance of gut microbiota-based approaches to simple non-invasive tools for the prediction of advanced fibrosis in NAFLD. 16S rRNA gene sequencing was performed in a cohort of 83 biopsy-proven NAFLD patients and 13 patients with non-invasively diagnosed NAFLD-cirrhosis. Random Forest models based on clinical data and sequencing results were compared with transient elastography, the NAFLD fibrosis score (NFS) and FIB-4 index. A Random Forest model containing clinical features and bacterial taxa achieved an area under the curve (AUC) of 0.87 which was only marginally superior to a model without microbiota features (AUC 0.85). The model that aimed to validate a published algorithm achieved an AUC of 0.71. AUC's for NFS and FIB-4 index were 0.86 and 0.85. Transient elastography performed best with an AUC of 0.93. Gut microbiota signatures might help to predict advanced fibrosis in NAFLD. However, transient elastography achieved the best diagnostic performance for the detection of NAFLD patients at risk for disease progression.
- Published
- 2020
- Full Text
- View/download PDF
42. High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD.
- Author
-
Lang S, Martin A, Farowski F, Wisplinghoff H, Vehreschild MJGT, Liu J, Krawczyk M, Nowag A, Kretzschmar A, Herweg J, Schnabl B, Tu XM, Lammert F, Goeser T, Tacke F, Heinzer K, Kasper P, Steffen HM, and Demir M
- Abstract
Overconsumption of carbohydrates and lipids are well known to cause nonalcoholic fatty liver disease (NAFLD), while the role of nutritional protein intake is less clear. In Western diet, meat and other animal products are the main protein source, with varying concentrations of specific amino acids. Whether the amount or composition of protein intake is associated with a higher risk for disease severity has not yet been examined. In this study, we investigated associations of dietary components with histological disease activity by analyzing detailed 14-day food records in a cohort of 61 patients with biopsy-proven NAFLD. Furthermore, we used 16S ribosomal RNA gene sequencing to detect associations with different abundances of the gut microbiota with dietary patterns. Patients with definite nonalcoholic steatohepatitis (NAFLD activity score of 5-8 on liver biopsy) had a significantly higher daily relative intake of protein compared with patients with a NAFLD activity score of 0-4 (18.0% vs. 15.8% of daily protein-based calories, P = 0.018). After adjustment for several potentially confounding factors, a higher protein intake (≥17.3% of daily protein-based calories) remained associated with definite nonalcoholic steatohepatitis, with an odds ratio of 5.09 (95% confidence interval 1.22-21.25, P = 0.026). This association was driven primarily by serine, glycine, arginine, proline, phenylalanine, and methionine. A higher protein intake correlated with a lower Bacteroides abundance and an altered abundance of several other bacterial taxa. Conclusion: A high protein intake was independently associated with more active and severe histological disease activity in patients with NAFLD. Further studies are needed to investigate the potential harmful role of dietary amino acids on NAFLD, with special attention to meat as their major source., (© 2020 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.)
- Published
- 2020
- Full Text
- View/download PDF
43. Potential biomarkers to predict outcome of faecal microbiota transfer for recurrent Clostridioides difficile infection.
- Author
-
Farowski F, Solbach P, Tsakmaklis A, Brodesser S, Cruz Aguilar MR, Cornely OA, Dettmer K, Higgins PG, Suerbaum S, Jazmati N, Oefner PJ, and Vehreschild MJGT
- Subjects
- Aged, Aged, 80 and over, Biomarkers metabolism, Clostridium Infections microbiology, Feces chemistry, Female, Humans, Male, Middle Aged, Recurrence, Treatment Outcome, Clostridium Infections therapy, Fecal Microbiota Transplantation, Gastrointestinal Microbiome, Lithocholic Acid metabolism
- Abstract
Background & Aims: Faecal microbiota transplantation (FMT) has proven high clinical efficacy in the management of recurrent Clostridioides difficile infection (rCDI) with cure rates of over 80% after a single treatment. Nevertheless, the reasons for failure in the remaining 20% remain elusive. The aim of the present study was to investigate different potential predictors of response to FMT., Methods: Faecal specimens of sixteen patients undergoing FMT for rCDI, as well as samples from the respective donors were collected and analyzed by 16S rRNA gene profiling, bile acid-inducible (baiCD) gene specific qPCR, and liquid chromatography tandem-mass spectrometry (LC-MS/MS) to quantify the concentrations of primary and secondary bile acids., Results: Using the faecal concentration of the secondary bile acid lithocholic acid (LCA)within the patient specimens, we were able to predict response to FMT (accuracy 95.2%, sensitivity 100%, specificity 90.9%). By combining the faecal LCA concentration with the urinary pCS concentration, an accuracy of 100% was achieved., Conclusion: LCA appears to be a promising marker candidate for prediction of clinical response to FMT. Other makers, such as urinary concentration of pCS, but not 3-IS, might be used to improve accuracy of prediction. Further studies are warranted to validate these candidate markers., (Copyright © 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
44. Controlling intestinal colonization of high-risk haematology patients with ESBL-producing Enterobacteriaceae: a randomized, placebo-controlled, multicentre, Phase II trial (CLEAR).
- Author
-
Dimitriou V, Biehl LM, Hamprecht A, Vogel W, Dörfel D, Peter S, Schafhausen P, Rohde H, von Lilienfeld-Toal M, Klassert TE, Slickers P, Ehricht R, Slevogt H, Christ H, Hellmich M, Farowski F, Tsakmaklis A, Higgins PG, Seifert H, and Vehreschild MJGT
- Subjects
- Adult, Aged, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Drug Resistance, Bacterial, Female, Gastrointestinal Microbiome, Humans, Immunocompromised Host, Male, Microbial Sensitivity Tests, Middle Aged, Carbapenem-Resistant Enterobacteriaceae drug effects, Carbapenem-Resistant Enterobacteriaceae genetics, Enterobacteriaceae Infections etiology, Enterobacteriaceae Infections prevention & control, Hematologic Diseases complications, Infection Control methods
- Abstract
Objectives: We assessed the efficacy and safety of an oral antimicrobial regimen for short- and long-term intestinal eradication of ESBL-producing Escherichia coli and Klebsiella pneumoniae (ESBL-EC/KP) in immunocompromised patients., Methods: We performed a randomized (2:1), double-blind multicentre Phase II study in four haematology-oncology departments. Patients colonized with ESBL-EC/KP received a 7 day antimicrobial regimen of oral colistin (2 × 106 IU 4×/day), gentamicin (80 mg 4×/day) and fosfomycin (three administrations of 3 g every 72 h), or placebo. Faecal, throat and urine specimens were collected on day 0, 6 ± 2, 11 ± 2, 28 ± 4 and 42 ± 4 after treatment initiation, and the quantitative burden of ESBL-EC/KP, resistance genes and changes in intestinal microbiota were analysed. Clinicaltrials.gov: NCT01931592., Results: As the manufacture of colistin powder was suspended worldwide, the study was terminated prematurely. Overall, 29 (18 verum/11 placebo) out of 47 patients were enrolled. The short-term intestinal eradication was marginal at day 6 (verum group 15/18, 83.3% versus placebo 2/11, 18.2%; relative risk 4.58, 95% CI 1.29-16.33; Fisher's exact test P = 0.001) and not evident at later timepoints. Quantitative analysis showed a significant decrease of intestinal ESBL-EC/KP burden on day 6. Sustained intestinal eradication (day 28 + 42) was not achieved (verum, 38.9% versus placebo, 27.3%; P = 0.299). In the verum group, mcr-1 genes were detected in two faecal samples collected after treatment. Microbiome analysis showed a significant decrease in alpha diversity and a shift in beta diversity., Conclusions: In this prematurely terminated study of a 7 day oral antimicrobial eradication regimen, short-term ESBL-EC/KP suppression was marginal, while an altered intestinal microbiota composition was clearly apparent., (© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
45. Usability of rectal swabs for microbiome sampling in a cohort study of hematological and oncological patients.
- Author
-
Biehl LM, Garzetti D, Farowski F, Ring D, Koeppel MB, Rohde H, Schafhausen P, Stecher B, and Vehreschild MJGT
- Subjects
- Cohort Studies, Female, Humans, Male, Enterobacteriaceae classification, Enterobacteriaceae growth & development, Enterococcus classification, Enterococcus genetics, Feces microbiology, Gastrointestinal Microbiome, Hematologic Neoplasms microbiology, Specimen Handling
- Abstract
Objectives: Large-scale clinical studies investigating associations between intestinal microbiota signatures and human diseases usually rely on stool samples. However, the timing of repeated stool sample collection cannot be predefined in longitudinal settings. Rectal swabs, being straightforward to obtain, have the potential to overcome this drawback. Therefore, we assessed the usability of rectal swabs for microbiome sampling in a cohort of hematological and oncological patients., Study Design: We used a pipeline for intestinal microbiota analysis from deep rectal swabs which was established and validated with test samples and negative controls. Consecutively, a cohort of patients from hematology and oncology wards was established and weekly deep rectal swabs taken during their admissions and re-admissions., Results: Validation of our newly developed pipeline for intestinal microbiota analysis from rectal swabs revealed consistent and reproducible results. Over a period of nine months, 418 rectal swabs were collected longitudinally from 41 patients. Adherence to the intended sampling protocol was 97%. After DNA extraction, sequencing, read pre-processing and filtering of chimeric sequences, 405 of 418 samples (96.9%) were eligible for further analyses. Follow-up samples and those taken under current antibiotic exposure showed a significant decrease in alpha diversity as compared to baseline samples. Microbial domination occurred most frequently by Enterococcaceae (99 samples, 24.4%) on family level and Enterococcus (90 samples, 22.2%) on genus level. Furthermore, we noticed a high abundance of potential skin commensals in 99 samples (24.4%)., Summary: Deep rectal swabs were shown to be reliable for microbiome sampling and analysis, with practical advantages related to high sampling adherence, easy timing, transport and storage. The relatively high abundance of putative skin commensals in this patient cohort may be of potential interest and should be further investigated. Generally, previous findings on alpha diversity dynamics obtained from stool samples were confirmed., Competing Interests: LMB has received lecture honoraria from Astellas Pharma and MSD and travel grants from 3M and Gilead. MJGTV has served at the speakers’ bureau of Pfizer, Merck, Gilead Sciences and Astellas Pharma, received research funding from 3M, DaVolterra, Astellas Pharma, Gilead Sciences and Merck and is a consultant to Berlin Chemie, Astellas Pharma and Merck. All other authors: none to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2019
- Full Text
- View/download PDF
46. Assessment of urinary 3-indoxyl sulfate as a marker for gut microbiota diversity and abundance of Clostridiales.
- Author
-
Farowski F, Els G, Tsakmaklis A, Higgins PG, Kahlert CR, Stein-Thoeringer CK, Bobardt JS, Dettmer-Wilde K, Oefner PJ, Vehreschild JJ, and Vehreschild MJGT
- Subjects
- Adult, Aged, Anti-Bacterial Agents pharmacology, Biodiversity, Clostridiales drug effects, Clostridiales genetics, Cohort Studies, Feces microbiology, Female, Humans, Male, Middle Aged, RNA, Ribosomal, 16S genetics, Biomarkers urine, Clostridiales classification, Clostridiales isolation & purification, Clostridium Infections diagnosis, Gastrointestinal Microbiome drug effects, Gastrointestinal Microbiome genetics, Indican urine
- Abstract
Objectives: After allogeneic hematopoietic stem cell transplantation (allo-HCT), urinary levels of 3-indoxyl sulfate (3-IS) correlate with the relative abundance of bacteria from the class Clostridia (RAC), and antibiotic treatment is considered the major determinant of this outcome. A high RAC has been associated with favorable outcome after allo-HCT and protection from Clostridium difficile infection (CDI). We assessed correlations between alpha diversity, RAC and urinary 3-IS levels in a non-allo-HCT clinical cohort of antibiotic treated patients to further explore 3-IS as a biomarker of reduced diversity and predisposition to CDI., Methods: Fecal and urinary specimens were analyzed from 40 non-allo-HCT hospitalized patients before and 9 ± 2 days after initiation of intravenous antibiotic treatment. Fecal microbiota were analyzed by 16s RNA sequencing and urinary 3-IS was analyzed by liquid chromatography-tandem mass spectrometry. Receiver operating characteristic (ROC) analysis was performed to assess the predictive value of 3-IS., Results: At a RAC cutoff of <30%, the binary logarithm of 3-IS (medium 3-IS: ≤2.5; high 3-IS: >2.5) was predictive with an accuracy of 82% (negative predictive value: 87%, positive predictive value 67%). Accuracy was improved by combing antibiotic history with 3-IS levels (accuracy 89%, npv 88%, ppv 92%)., Conclusion: In conjunction with patient antibiotic history, 3-IS is a candidate marker to predict RAC.
- Published
- 2019
- Full Text
- View/download PDF
47. Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infection.
- Author
-
Biehl LM, Cruz Aguilar R, Farowski F, Hahn W, Nowag A, Wisplinghoff H, and Vehreschild MJGT
- Subjects
- Female, Germany, Humans, Middle Aged, Recurrence, Treatment Outcome, Fecal Microbiota Transplantation, Kidney Transplantation, Transplant Recipients, Urinary Tract Infections therapy
- Abstract
Purpose: We report on a kidney transplant recipient treated with fecal microbiota transplantation (FMT) for recurrent urinary tract infections., Methods: FMT was administered via frozen capsulized microbiota. Before and after FMT, urinary, fecal and vaginal microbiota compositions were analyzed., Results: The patient remained without symptoms after FMT., Conclusions: Underlying mechanisms of action need to be addressed in depth by future research.
- Published
- 2018
- Full Text
- View/download PDF
48. Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children.
- Author
-
Gastine S, Lehrnbecher T, Müller C, Farowski F, Bader P, Ullmann-Moskovits J, Cornely OA, Groll AH, and Hempel G
- Subjects
- Administration, Intravenous, Administration, Oral, Adolescent, Area Under Curve, Child, Female, Humans, Male, Models, Theoretical, Monte Carlo Method, Young Adult, Voriconazole administration & dosage, Voriconazole pharmacokinetics
- Abstract
The pharmacokinetic variability of voriconazole (VCZ) in immunocompromised children is high, and adequate exposure, particularly in the first days of therapy, is uncertain. A population pharmacokinetic model was developed to explore VCZ exposure in plasma after alternative dosing regimens. Concentration data were obtained from a pediatric phase II study. Nonlinear mixed effects modeling was used to develop the model. Monte Carlo simulations were performed to test an array of three-times-daily (TID) intravenous dosing regimens in children 2 to 12 years of age. A two-compartment model with first-order absorption, nonlinear Michaelis-Menten elimination, and allometric scaling best described the data (maximal kinetic velocity for nonlinear Michaelis-Menten clearance [ V
max ] = 51.5 mg/h/70 kg, central volume of distribution [ V1 ] = 228 liters/70 kg, intercompartmental clearance [ Q ] = 21.9 liters/h/70 kg, peripheral volume of distribution [ V2 ] = 1,430 liters/70 kg, bioavailability [ F ] = 59.4%, Km = fixed value of 1.15 mg/liter, absorption rate constant = fixed value of 1.19 h-1 ). Interindividual variabilities for Vmax , V1 , Q , and F were 63.6%, 45.4%, 67%, and 1.34% on a logit scale, respectively, and residual variability was 37.8% (proportional error) and 0.0049 mg/liter (additive error). Monte Carlo simulations of a regimen of 9 mg/kg of body weight TID simulated for 24, 48, and 72 h followed by 8 mg/kg two times daily (BID) resulted in improved early target attainment relative to that with the currently recommended BID dosing regimen but no increased rate of accumulation thereafter. Pharmacokinetic modeling suggests that intravenous TID dosing at 9 mg/kg per dose for up to 3 days may result in a substantially higher percentage of children 2 to 12 years of age with adequate exposure to VCZ early during treatment. Before implementation of this regimen in patients, however, validation of exposure, safety, and tolerability in a carefully designed clinical trial would be needed., (Copyright © 2017 American Society for Microbiology.)- Published
- 2017
- Full Text
- View/download PDF
49. Low penetration of caspofungin into cerebrospinal fluid following intravenous administration of standard doses.
- Author
-
Strenger V, Farowski F, Müller C, Hofer N, Dornbusch HJ, Sperl D, Lackner H, Benesch M, and Urban C
- Subjects
- Administration, Intravenous, Adolescent, Caspofungin, Child, Child, Preschool, Chromatography, Liquid, Female, Humans, Infant, Male, Prospective Studies, Serum chemistry, Tandem Mass Spectrometry, Time Factors, Antifungal Agents administration & dosage, Antifungal Agents pharmacokinetics, Cerebrospinal Fluid chemistry, Echinocandins administration & dosage, Echinocandins pharmacokinetics, Lipopeptides administration & dosage, Lipopeptides pharmacokinetics
- Abstract
The kinetics of caspofungin (CAS) in cerebrospinal fluid (CSF) following intravenous (i.v.) administration has been studied exclusively in animal models. Human data are missing so far. In this study, 13 CSF samples were obtained at different time points following i.v. infusion of CAS in ten paediatric haemato-/oncological patients (age range 1.0-14.2 years, median 8.6 years) without signs of central nervous system (CNS) infection (n = 10 samples) or with infectious meningitis (n = 3 samples). Serum samples were obtained concurrently. Liquid chromatography-tandem mass spectrometry was used for CAS quantification. Whilst CAS serum levels were in the expected range, varying between 0.6 and 20.3 µg/mL (median 7.0 µg/mL), 11 of 13 CSF levels were below the limit of detection of 0.084 µg/mL at 3.0-48.0 h (median 23.3 h) following i.v. infusion. Only two (of three) levels in patients with bacterial meningitis were above the limit of detection (0.3 µg/mL and 0.09 µg/mL, respectively). These results indicate the low capacity of CAS to penetrate into the CNS even in inflamed meninges. Monotherapy with standard doses of CAS appears not to be suitable for treatment of fungal CNS infections., (Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
50. High Intracellular Concentrations of Posaconazole Do Not Impact on Functional Capacities of Human Polymorphonuclear Neutrophils and Monocyte-Derived Macrophages In Vitro.
- Author
-
Farowski F, Cornely OA, and Hartmann P
- Subjects
- Antifungal Agents adverse effects, Aspergillosis microbiology, Aspergillus fumigatus drug effects, Cell Movement drug effects, Cell Movement immunology, Cells, Cultured, Humans, Macrophages drug effects, Neutrophils drug effects, Reactive Oxygen Species metabolism, Spores, Fungal drug effects, Antifungal Agents pharmacology, Aspergillosis drug therapy, Aspergillus fumigatus immunology, Macrophages immunology, Neutrophils immunology, Spores, Fungal growth & development, Triazoles adverse effects, Triazoles pharmacology
- Abstract
Posaconazole is a commonly used antifungal for the prophylaxis and treatment of invasive fungal infections. We previously demonstrated that the intracellular concentration of posaconazole in peripheral blood mononuclear cells (PBMCs) and polymorphonuclear neutrophils (PMNs) was greatly increased compared to the plasma concentration. As these professional phagocytes are crucial to combat fungal infections, we set out to investigate if and how, beneficial or deleterious, this high loading of intracellular posaconazole impacts the functional capacities of these cells. Here, we show that high intracellular concentrations of posaconazole do not significantly impact PMN and monocyte-derived macrophage function in vitro In particular, killing capacity and cytoskeletal features of PMN, such as migration, are not affected, indicating that these cells serve as vehicles for posaconazole to the site of infection. Moreover, since posaconazole as such slowed the germination of Aspergillus fumigatus conidia, infected neutrophils released less reactive oxygen species (ROS). Based on these findings, we propose that the delivery of posaconazole by neutrophils to the site of Aspergillus species infection warrants control of the pathogen and preservation of tissue integrity at the same time., (Copyright © 2016, American Society for Microbiology. All Rights Reserved.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.